Search results for "AGENTS"

showing 10 items of 7330 documents

Neuropharmacology of the mesolimbic system and associated circuits on social hierarchies

2018

Most socially living species are organized hierarchically, primarily based on individual differences in social dominance. Dominant individuals typically gain privileged access to important resources, such as food, mating partners and territories, whereas submissive conspecifics are often devoid of such benefits. The benefits associated with a high social status provide a strong incentive to become dominant. Importantly, motivational- and reward-related processes are regulated, to a large extent, by the mesolimbic system. Consequently, several studies point to a key role for the mesolimbic system in social hierarchy formation. This review summarizes the growing body of literature that implic…

0301 basic medicineDopamine AgentsHierarchy Social03 medical and health sciencesCellular and Molecular NeuroscienceNeuropharmacology0302 clinical medicineNeurochemicalLimbic SystemmedicineAnimalsHumansNeurochemistryNeuropharmacologyPharmacologyDopaminergic NeuronsVentral Tegmental AreaSocial stratification030104 developmental biologyDominance (ethology)AnxietyNerve Netmedicine.symptomPsychologyNeuroscience030217 neurology & neurosurgerySocial behaviorSocial statusNeuropharmacology
researchProduct

Design, synthesis and preliminary evaluation of dopamine-amino acid conjugates as potential D1 dopaminergic modulators.

2016

Abstract The dopamine-amino acid conjugate DA-Phen was firstly designed to obtain a useful prodrug for the therapy of Parkinson's disease, but experimental evidence shows that it effectively interacts with D1 dopamine receptors (D1DRs), leading to an enhancement in cognitive flexibility and to the development of adaptive strategies in aversive mazes, together with a decrease in despair-like behavior. In this paper, homology modelling, molecular dynamics, and site mapping of D1 receptor were carried out with the aim of further performing docking studies on other dopamine conjugates compared with D1 agonists, in the attempt to identify new compounds with potential dopaminergic activity. Two n…

0301 basic medicineDopamineDopamine AgentsChemistry Techniques SyntheticPharmacology01 natural sciencesDocking03 medical and health sciencesDopamine receptor D1Drug StabilityDopamineCatalytic DomainDrug DiscoverymedicineAnimalsHumansAmino Acidschemistry.chemical_classificationConjugatePharmacologyPCA010405 organic chemistryChemistrySynthesiDrug Discovery3003 Pharmaceutical ScienceReceptors Dopamine D1DopaminergicOrganic ChemistryBrainGeneral MedicineProdrug0104 chemical sciencesAmino acidAmino acidRatsMolecular Docking Simulation030104 developmental biologyBiochemistryDocking (molecular)Dopamine receptorDrug DesignMolecular modellingConjugatemedicine.drugEuropean journal of medicinal chemistry
researchProduct

The therapeutic potential of inorganic polyphosphate: A versatile physiological polymer to control coronavirus disease (COVID-19).

2021

Rationale: The pandemic caused by the novel coronavirus SARS-CoV-2 is advancing rapidly. In particular, the number of severe courses of the disease is still dramatically high. An efficient drug therapy that helps to improve significantly the fatal combination of damages in the airway epithelia, in the extensive pulmonary microvascularization and finally multiorgan failure, is missing. The physiological, inorganic polymer, polyphosphate (polyP) is a molecule which could prevent the initial phase of the virus life cycle, the attachment of the virus to the target cells, and improve the epithelial integrity as well as the mucus barrier. Results: Surprisingly, polyP matches perfectly with the ca…

0301 basic medicineDrug Evaluation PreclinicalMedicine (miscellaneous)Virus AttachmentRespiratory MucosaReviewmedicine.disease_causeAntiviral Agents03 medical and health sciencesMice0302 clinical medicinePolyphosphatesmedicineAnimalsHumansMode of actionReceptorPharmacology Toxicology and Pharmaceutics (miscellaneous)PandemicsMUC1Coronaviruschemistry.chemical_classificationChemistrySARS-CoV-2MucinMucinsCOVID-19Epithelial CellspolyphosphateMucusdigestive system diseasesCell biologyCOVID-19 Drug TreatmentDisease Models Animal030104 developmental biology030220 oncology & carcinogenesisAlkaline phosphataseNanoparticlesGlycoproteinviral receptor-binding domainTheranostics
researchProduct

Reversal of multidrug resistance by Marsdenia tenacissima and its main active ingredients polyoxypregnanes.

2016

Abstract Ethnopharmacological relevance Multidrug resistance (MDR) of cancer is often associated with the overexpression of ATP-binding cassette (ABC) transporters, such as P-glycoprotein (P-gp), multidrug resistance-associated protein-1 (MRP-1) and breast cancer resistance protein (BCRP or ABCG2), in cancer cells, which facilitates the active efflux of a wide variety of chemotherapeutic drugs out of the cells. Marsdenia tenacissima is a traditional Chinese medicinal herb that has long been clinically used for treatment of cancers, particularly in combinational use with anticancer drugs. Polyoxypregnanes (POPs) are identified as main constituents of this herb, and three of them have been re…

0301 basic medicineDrugAbcg2media_common.quotation_subjectAntineoplastic AgentsPharmacology03 medical and health sciences0302 clinical medicineCell Line TumorNeoplasmsDrug DiscoverymedicineATP Binding Cassette Transporter Subfamily G Member 2HumansATP Binding Cassette Transporter Subfamily B Member 1P-glycoproteinmedia_commonPharmacologybiologyChemistryPlant ExtractsCancerMarsdeniaTransportermedicine.diseaseFlow CytometryPregnanesDrug Resistance MultipleNeoplasm ProteinsMultiple drug resistanceGene Expression Regulation NeoplasticMolecular Docking Simulation030104 developmental biologyDrug Resistance Neoplasm030220 oncology & carcinogenesisCancer cellbiology.proteinEffluxMultidrug Resistance-Associated ProteinsJournal of ethnopharmacology
researchProduct

Cancer combination therapies with artemisinin-type drugs

2017

Artemisia annua L. is a Chinese medicinal plant, which is used throughout Asia and Africa as tea or press juice to treat malaria. The bioactivity of its chemical constituent, artemisinin is, however, much broader. We and others found that artemisinin and its derivatives also exert profound activity against tumor cells in vitro and in vivo. Should artemisinin-type drugs be applied routinely in clinical oncology in the future, then it should probably be as part of combination therapy regimens rather than as monotherapy. In the present review, I give a comprehensive overview on synergistic and additive effects of artemisinin-type drugs in combination with different types of cytotoxic agents an…

0301 basic medicineDrugCombination therapymedicine.medical_treatmentmedia_common.quotation_subjectArtemisia annuaDrug resistancePharmacologyBiochemistry03 medical and health scienceschemistry.chemical_compound0302 clinical medicineIn vivoCell Line TumorNeoplasmsAntineoplastic Combined Chemotherapy Protocolsparasitic diseasesmedicineAnimalsHumansDrug InteractionsArtemisininmedia_commonPharmacologyBiological ProductsChemotherapyNatural productbiologybusiness.industryDrug SynergismDrugs Investigationalbiology.organism_classificationAntineoplastic Agents PhytogenicCombined Modality TherapyArtemisininsDrug Resistance Multiple030104 developmental biologychemistryDrug Resistance Neoplasm030220 oncology & carcinogenesisChemical and Drug Induced Liver InjurybusinessSesquiterpenesmedicine.drugBiochemical Pharmacology
researchProduct

Drug metabolism by cultured human hepatocytes: how far are we from the in vivo reality?

2004

The investigation of metabolism is an important milestone in the course of drug development. Drug metabolism is a determinant of drug pharmacokinetics variability in human beings. Fundamental to this are phenotypic differences, as well as genotypic differences, in the expression of the enzymes involved in drug metabolism. Genotypic variability is easy to identify by means of polymerase chain reaction-based or DNA chip-based methods, whereas phenotypic variability requires direct measurement of enzyme activities in liver, or, indirectly, measurement of the rate of metabolism of a given compound in vivo. There is a great deal of phenotypic variability in human beings, only a minor part being…

0301 basic medicineDrugDiclofenacmedia_common.quotation_subjectBiologyPharmacologyToxicologyGeneral Biochemistry Genetics and Molecular Biology03 medical and health sciences0302 clinical medicineCytochrome P-450 Enzyme SystemIn vivoGenetic variationmedicineHumansCells Culturedmedia_common030102 biochemistry & molecular biologyAnti-Inflammatory Agents Non-SteroidalGenetic VariationGeneral MedicineMetabolismIn vitroMedical Laboratory TechnologyDrug developmentBiochemistryLiverPharmaceutical Preparations030220 oncology & carcinogenesisMultigene FamilyHepatocytesAceclofenacDrug metabolismmedicine.drugAlternatives to laboratory animals : ATLA
researchProduct

Abacavir Induces Arterial Thrombosis in a Murine Model.

2018

Background The purinergic system is known to underlie prothrombotic and proinflammatory vascular programs, making the profile of experimental actions demonstrated by abacavir compatible with thrombogenesis. However, direct evidence of a prothrombotic effect by the drug has been lacking. Methods The present study appraised the effects of abacavir in a well-validated animal model of arterial thrombosis. The role of ATP-P2X7 receptors in the actions of the drug was also assessed, and the actions of recognized vascular-damaging agents and other nucleoside reverse-transcriptase inhibitors (NRTIs) were evaluated and compared to those of abacavir. Results Abacavir dose-dependently promoted thrombu…

0301 basic medicineDrugMaleAnti-HIV Agentsmedia_common.quotation_subject030204 cardiovascular system & hematologyPharmacologyProinflammatory cytokine03 medical and health sciences0302 clinical medicineimmune system diseasesAbacavirmedicineImmunology and AllergyAnimalsRofecoxibmedia_commonMice KnockoutDose-Response Relationship Drugbusiness.industryPurinergic receptorAntagonistvirus diseasesThrombosisPurinergic signallingmedicine.diseaseThrombosisDideoxynucleosidesDisease Models Animal030104 developmental biologyInfectious DiseasesReceptors Purinergic P2X7businessmedicine.drugThe Journal of infectious diseases
researchProduct

Shikonin derivatives for cancer prevention and therapy.

2019

Abstract Phytochemicals gained considerable interest during the past years as source to develop new treatment options for chemoprevention and cancer therapy. Motivated by the fact that a majority of established anticancer drugs are derived in one way or another from natural resources, we focused on shikonin, a naphthoquinone with high potentials to be further developed as preventive or therapeutic drug to fight cancer. Shikonin is the major chemical component of Lithospermum erythrorhizon (Purple Cromwell) roots. Traditionally, the root extract has been applied to cure dermatitis, burns, and wounds. Over the past three decades, the anti-inflammatory and anticancer effects of root extracts, …

0301 basic medicineDrugModels MolecularCancer Researchmedicine.medical_treatmentmedia_common.quotation_subject03 medical and health sciencesStructure-Activity Relationship0302 clinical medicineNeoplasmsMedicineAnimalsHumansmedia_commonCancer preventionTraditional medicinebiologybusiness.industryCancerImmunotherapyLithospermum erythrorhizonbiology.organism_classificationmedicine.diseaseAntineoplastic Agents PhytogenicClinical trialRadiation therapy030104 developmental biologyOncologyPhytochemical030220 oncology & carcinogenesisbusinessDrugs Chinese HerbalNaphthoquinonesCancer letters
researchProduct

Kinase Inhibitors in Multitargeted Cancer Therapy

2017

The old-fashioned anticancer approaches, aiming in arresting cancer cell proliferation interfering with non-specific targets (e.g. DNA), have been replaced, in the last decades, by more specific target oriented ones. Nonetheless, single-target approaches have not always led to optimal outcomes because, for its complexity, cancer needs to be tackled at various levels by modulation of several targets. Although at present, combinations of individual single-target drugs represent the most clinically practiced therapeutic approaches, the modulation of multiple proteins by a single drug, in accordance with the polypharmacological strategy, has become more and more appealing. In the perspective of…

0301 basic medicineDrugNiacinamideIndolesPyridinesmedia_common.quotation_subjectPharmacologyBioinformaticsBiochemistryReceptor tyrosine kinase03 medical and health sciencesCrizotinibPiperidinesMultitargeted drugs anticancer agents polypharmacology tyrosine kinase receptors oncogene addiction tumor microenvironment FDA-approved drugsNeoplasmsDrug DiscoverymedicineSunitinibHumansAnilidesPyrrolesProtein Kinase Inhibitorsmedia_commonPharmacologyTumor microenvironmentbiologybusiness.industryPhenylurea CompoundsOrganic ChemistryImidazolesCancerReceptor Protein-Tyrosine KinasesSorafenibmedicine.diseaseOncogene AddictionSettore CHIM/08 - Chimica FarmaceuticaClinical trialPyridazines030104 developmental biologyMechanism of actionbiology.proteinImatinib MesylateQuinazolinesMolecular MedicinePyrazolesmedicine.symptombusinessTyrosine kinase
researchProduct

Towards patient stratification and treatment in the autoimmune disease lupus erythematosus using a systems pharmacology approach

2015

Drug development in Systemic Lupus Erythematosus (SLE) has been hindered by poor translation from successful preclinical experiments to clinical efficacy. This lack of success has been attributed to the high heterogeneity of SLE patients and to the lack of understanding of disease physiopathology. Modelling approaches could be useful for supporting the identification of targets, biomarkers and patient subpopulations with differential response to drugs. However, the use of traditional quantitative models based on differential equations is not justifiable in a sparse data situation. Boolean networks models are less demanding on the required data to be implemented and can provide insights into…

0301 basic medicineDrugSystems biologymedia_common.quotation_subjectPharmaceutical ScienceAntineoplastic AgentsDiseaseBioinformaticsAutoimmune Diseases03 medical and health sciencesmedicineAnimalsCluster AnalysisHumansLupus Erythematosus SystemicComputer Simulationmedia_commonAutoimmune diseaseLupus erythematosusbusiness.industrySystems Biologymedicine.diseaseTreatment Outcome030104 developmental biologyDrug developmentPharmacology ClinicalbusinessBiological networkSystems pharmacologyEuropean Journal of Pharmaceutical Sciences
researchProduct